research centre

At the HIV Vaccine World Congress, which is taking place in Barcelona between the 7^th and 10^th October, Catalan researchers presented a vaccine prototype that has proven to be effective in clinical studies conducted with mice and monkeys. The vaccine stimulates the creation of antibodies and attacks infected cells. The prototype has been created by the Catalan programme to develop a vaccine against HIV, HIVACAT. According to the programme’s Scientific Director, Christian Brander, the vaccine could eventually also be used as a therapeutic treatment.

According to a medical study developed in Barcelona’s Hospital Clínic, fetuses conceived by assisted reproduction have changes in their heart and arteries, which begin even before birth and persist in the postnatal period. These changes represent a significant increase in cardiovascular risk in adulthood. However, the researchers point out that this situation is reversible from the beginning of life through a diet rich in omega3 and other factors. In addition, they strongly emphasised that this is only a risk factor and not a disease. The study leader, Eduard Gratacós, said that “it's a message of opportunity, not alarm”. Furthermore, they also recommend monitoring the blood pressure of these babies.

The Catalan Institute of Photonic Sciences (ICFO), based in Greater Barcelona, is the highest ranked centre in the world in the fields of physics and astronomy, according to a survey carried out by Excellence Mapping. This ranking sorts the world’s leading research centres according to 17 different areas of academia. The ICFO was ranked first in physics and astronomy, while the Catalan Institute for Research and Advanced Studies (ICREA) was placed third in this category. Other Catalonia-based institutions that were included in the list were: the Institute for High Energy Physics, IFAE (18^th place), the Universitat Autònoma of Barcelona (UAB) and the Polytechnic University of Barcelona (UPC). The Director of the ICFO, Lluís Torner, told the CNA that the Catalan model of research is “highly competitive”.

Christian Brander is a researcher at the IrsiCaixa AIDS Research Institute and Scientific Director of HIVACAT, the programme for the development of a HIV vaccine. He graduated from the University of Bern in 1994 with a PhD in Immunology and has spent 13 years at Harvard University focusing on cellular immunity to viral infections.

The Catalan research centre has unveiled a new 625-square-metre space where the Academic Research Organisation (ARO) will be based. The ARO will provide support for clinical trials developed throughout the world regarding quality control, methodological, regulatory, statistical and management aspects. Furthermore, the new space has 7 medical boxes, nursery support and a lab to process the samples, which will provide an integral service for clinical trials. The new facilities will be able to host between 750 and 1,100 patients per year and work on 350 trials. It cost €1.2 million, which came from public funds.

50% of tumours are related to mutations of this gene, according to the researchers. A study developed by the Bellvitge Institute of Biomedical Research (IBIDELL), based in Greater Barcelona, and the University of Cincinnati have discovered the role of the noncoding 5S rRNA molecule. This molecule regulates the P53 Tumour Suppressor Gene, which protects healthy cells from turning into cancerous cells. When the cell functions correctly, the levels of P53 are low and stable, but when something wrong is detected, the levels increase and cause the cell’s death, avoiding the development of a tumour. The director of the study, George Thomas, explained that understanding how the P53 works and regulates itself is extremely important since “more than half of the tumours present mutations of this gene”.

The exposure to music during in vitro fertilisation has a positive impact on the fecundity rate of egg cells according to a study developed by the assisted reproduction centre Institut Marquès, based in Barcelona. The study concludes that the micro vibrations in the music shake the culture liquid in which the ovum swims and this improves the distribution of nutrients and also avoids the accumulation of toxic products. As a result, the fertilisation of the ovum is facilitated and the success rate is improved by 4.8%. Three styles of music were tested (pop, heavy metal and classical) but no significant differences were observed in relation to the different frequencies.

Telefónica’s R&D centre in Barcelona’s 22@ technological district will lead the company’s innovation internationally and will significantly increase its staff numbers, which currently stands at 220 workers. The decision strengthens Barcelona’s position as the Mobile World Capital, as it already hosts the main event of the mobile technology industry at an international level. In total, Telefónica has 6 R&D centres spread throughout the world. Besides Barcelona, the company’s innovation centres are based in Silicon Valley, Sao Paulo, London, Tel Aviv and Madrid. The Barcelona centre is now celebrating its 10th anniversary. In the last decade, Telefónica has invested up to €200 million in its Catalan centre, €28 million of which was in 2012.

Mateu Hernández is the General Director of Barcelona Global, an independent private association that is trying to make Barcelona one of the best cities in the world to attract talent and business activity. Its activities are similar to associations like Partnership for New York, Berlín & Partners and London & Partners, for example. Barcelona Global is made up of the main research centres in the city, prestigious professionals from the Catalan capital or related to it, and more than thirty of the most powerful and innovative companies in Barcelona.

The vaccine works by re-introducing immune system cells, which have previously been extracted and modified, in order to avoid the destruction of beta cells, which are those producing insulin. The vaccine has been developed by researchers from the Germans Trias Hospital in Badalona, in Greater Barcelona. Furthermore, in February, another group of Catalan scientists announced the cure of Type 1 Diabetes in two dogs, which is the first time this has been successful in large animals. In the last few years, Catalonia and especially Greater Barcelona have become a world centre within the biomedicine sector.

The Catalan Institute of Human Paleoecology and Social Evolution (IPHES) is one of the 3 centres with the highest scientific production internationally in its field. It is directed by Eudald Carbonell, the palaeontologist who has been directing the Atapuerca site since its discovery. Atapuerca was where the oldest human specimens in Europe were found, the so-called Homo Antecessor. The IPHES started its activities in 2006 but due to its increasing relevance it needed more room. Since last June the institute has moved to a new building in the Sescelades Campus of the Rovira i Virgili University (URV) in southern Catalonia. On Friday the President of the Catalan Government, Artur Mas, officially unveiled the facilities. The new building cost €6 million and it has 3,000 square metres to host 62 members of staff.

The Catalan Institute of Oncology (ICO) has introduced a world pioneering technique which allows four out of five patients who cannot undergo surgery to survive the illness. This technique causes less after-effects than the traditional radiotherapy. Furthermore, statistics show that with the regular treatment, two thirds of these patients die. However, Ferran Gadea, the Head of the Radiotherapy and Oncology Service, says that the best option to cure a lung cancer is still to undergo the operation when possible.

This is a real stride for the cancer research. The effects of a protein called condensing on colorectal cancer have been found out by a team of Molecular Biology and Biochemistry experts, at the Research Centre for Nanomedicine (CIBBIN-Nanomedicine) at the Vall d'Hebon Research Institute. The researchers have discovered that condensin helps the tumor cells to divide rapidly, so its inhibition leads to the death of tumour cells. The results of this research were published in the 'Journal of Biology and Chemistry', and they constitute a real hope for the fight against colorectal cancer.

The technique started in Catalonia in 2007 and by 2011 it was practiced on 40% of patients with renal failure. The Catalan Health Ministry hopes to cover 100% of the cases within the next 5 to 10 years. In the United States it started being used a year ago as they were waiting for clinical results to expand its use. Now, a clinical study on 900 patients from 27 different Catalan centres has proved that the technique reduces mortality by 30% on patients with kidney failure within the first three years. In addition, it improves quality of life, reduces hospitalisations by 22% and it also makes hypotension episodes drop by 28%.

Researchers from the Catalan Institute of Oncology have led the largest international study on breast cance4r and nutrition. The 8-year study has been based on 335,062 women between 35 and 70 years old. It has involved 23 centres in 10 European countries and it has been published in the ‘International Journal of Cancer’. The study concludes that the Mediterranean diet can reduce the risk of breast cancer by 6% among women in general and 7% in the case of post-menopausal patients.